INT250628

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 14
Disease Relevance 7.05
Pain Relevance 1.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoskeleton (MCPH1) intracellular (MCPH1) microtubule organizing center (MCPH1)
cytoplasm (MCPH1)
MCPH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 13 99.58 Very High Very High Very High
antagonist 84 99.52 Very High Very High Very High
Bioavailability 18 97.44 Very High Very High Very High
aspirin 14 84.28 Quite High
Inflammation 35 84.08 Quite High
Potency 12 80.52 Quite High
Serotonin 35 73.44 Quite High
chemokine 7 68.36 Quite High
cytokine 21 62.64 Quite High
cva 14 61.20 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 1050 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 35 99.56 Very High Very High Very High
Toxicity 6 96.84 Very High Very High Very High
Apoptosis 34 91.84 High High
Hypertrophy 252 91.40 High High
Overdose 42 90.84 High High
Adhesions 14 86.56 High High
INFLAMMATION 56 84.08 Quite High
Pulmonary Heart Disease 7 83.12 Quite High
Dyspnea 7 81.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Uptake of GHB in MDA-MB231 cells was inhibited by the classic MCT inhibitors CHC, phloretin and pCMB with uptake being approximately 60% of control cells (10).
Negative_regulation (inhibitors) of MCT
1) Confidence 0.17 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0 Pain Relevance 0
Table II provides a summary of currently identified substrates and inhibitors of functionally characterized MCT isoforms from humans and rats.
Negative_regulation (inhibitors) of MCT
2) Confidence 0.14 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0 Pain Relevance 0
Furthermore, GHB has been demonstrated to be both a substrate and inhibitor for a number of MCT isoforms (10–12,53).
Negative_regulation (inhibitor) of MCT
3) Confidence 0.12 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0 Pain Relevance 0.06
These data suggest that flavonoids such as luteolin are potent MCT inhibitors both in vitro and in vivo.
Negative_regulation (inhibitors) of MCT
4) Confidence 0.12 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0.05 Pain Relevance 0.04
Additional in vitro and in vivo studies were conducted to evaluate novel MCT inhibitors and their potential to increase GHB renal clearance and overall pharmacokinetics.
Negative_regulation (evaluate) of MCT
5) Confidence 0.12 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0.19 Pain Relevance 0
In addition, inhibition of MCT-mediated intestinal absorption may substantially decrease drug bioavailability.
Negative_regulation (inhibition) of MCT associated with bioavailability
6) Confidence 0.12 Published 2008 Journal AAPS J Section Body Doc Link PMC2574616 Disease Relevance 0 Pain Relevance 0.05
For males and females together, there was a significant global decline in MCT with age, (R2 = 0.34, B1 = ? 
Negative_regulation (decline) of MCT
7) Confidence 0.03 Published 2009 Journal Neuroimage Section Body Doc Link PMC2741580 Disease Relevance 0.05 Pain Relevance 0
An intramuscular injection of adeno-associated virus (AAV) vector harboring the PGIS gene (AAV-PGIS) also prevented MCT-induced PAH in rats [57].

2.2.4.

Negative_regulation (prevented) of MCT-induced associated with pulmonary hypertension
8) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.82 Pain Relevance 0.10
Combination therapy with oral sildenafil, a phosphodiesterase (PDE)-5 inhibitor, and beraprost, an oral prostacyclin analogue, attenuated the development of MCT-induced PAH more than with either drug alone [10].
Negative_regulation (development) of MCT-induced associated with pulmonary hypertension
9) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.87 Pain Relevance 0.03
Oral sildenafil, a PDE5 inhibitor, prevented (in a study in which sildenafil was given 1 day after MCT) and reversed (in a study in which sildenafil was given 3 weeks after MCT) the development of PAH in MCT-treated rats, associated with a reduction in the ETA-receptor density in SMCs of pulmonary small arteries (diameter < 100??
Negative_regulation (given) of MCT associated with pulmonary hypertension
10) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.00 Pain Relevance 0.33
Elastase inhibitors were shown to reverse advanced MCT-induced pulmonary vascular disease.
Negative_regulation (reverse) of MCT-induced associated with increased venous pressure under development
11) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.16 Pain Relevance 0.06
Oral sildenafil, a PDE5 inhibitor, prevented (in a study in which sildenafil was given 1 day after MCT) and reversed (in a study in which sildenafil was given 3 weeks after MCT) the development of PAH in MCT-treated rats, associated with a reduction in the ETA-receptor density in SMCs of pulmonary small arteries (diameter < 100??
Negative_regulation (development) of MCT associated with pulmonary hypertension
12) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.95 Pain Relevance 0.30
Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) markedly attenuated MCT-induced PAH and improved survival in rats.
Negative_regulation (attenuated) of MCT-induced associated with pulmonary hypertension and agonist
13) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.03 Pain Relevance 0.16
A nonspecific endothelin-receptor antagonist, bosentan was shown to blunt MCT-induced PAH in rats [17].
Negative_regulation (blunt) of MCT-induced associated with pulmonary hypertension and antagonist
14) Confidence 0.02 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.92 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox